What’s the current market cap for Aker BioMarine AS stock?

Aker BioMarine AS (AKBM) has a market cap of Nkr9.7B as of May 31, 2026.

What is the P/E ratio for Aker BioMarine AS stock?

The price to earnings (P/E) ratio for Aker BioMarine AS (AKBM) stock is 0 as of May 31, 2026.

Does Aker BioMarine AS stock pay dividends?

No, Aker BioMarine AS (AKBM) stock does not pay dividends to its shareholders as of May 31, 2026.

When is the next Aker BioMarine AS dividend payment date?

Aker BioMarine AS (AKBM) stock does not pay dividends to its shareholders.

What is the beta indicator for Aker BioMarine AS?

Aker BioMarine AS (AKBM) has a beta rating of 0.26. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Aker BioMarine AS stock | NkrAKBM Share Price

07:00

08:50

10:40

12:30

14:20

About Aker BioMarine AS

Aker BioMarine AS is a biotechnology company focused on the sustainable harvesting, production, and distribution of krill-based products. Its core business operates within the marine biotechnology industry, emphasizing krill-derived ingredients for the health and nutrition sectors. The company's main products include krill oil for human consumption, utilized in dietary supplements, and krill meal used in feed for aquaculture. Headquartered in Oslo, Norway, Aker BioMarine maintains operations in the Southern Ocean where it conducts its krill harvesting activities. A unique aspect of its strategic positioning is its commitment to sustainability, which is underpinned by proprietary technology and practices designed to minimize environmental impact and ensure the responsible management of marine resources.

Ticker

Nkr AKBM

Sector

Consumer Essentials

Primary listing

XOSL

Employees

258

Headquarters

Lysaker, Norway

Website

www.akerbiomarine.com

AKBM Metrics

BasicAdvanced

kr 9.7bn

-kr 2.39

0.26

Bulls say / Bears say

The Human Health Ingredients segment generated USD 32.7 million in revenue in Q4 2025, up 28% year-over-year, with adjusted EBITDA in the segment rising 59% to USD 14.1 million, driven by better pricing and higher volumes.

Aker BioMarine launched a new krill oil brand in Costco during Q4 2025, with the listing showing strong initial results and attracting new customers in a key U.S. retail channel.

For Q1 2026, the company forecasts krill oil revenues to grow between 15% and 30% year-over-year, signaling robust underlying demand and strong pricing within its main ingredients business.

Consumer Health Products revenue dropped 8% year-over-year to USD 26.9 million in Q4 2025, reflecting ongoing weakness in drugstore channels and soft demand in end markets.

The Emerging Business segment posted an adjusted EBITDA loss of USD 0.5 million in Q4 2025, highlighting continued cash outflows and uncertainty regarding future profitability.

On April 1, 2026, an environmental activist ship intentionally struck Aker QRILL’s Norwegian-flagged trawler Antarctic Sea, causing minor hull damage near the diesel tank and drawing attention to growing operational and reputational risks.

Data summarised monthly by Lightyear AI. Last updated on 16 May 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Market data provided by CBOE Europe and Deutsche Börse.

Buy Nkr AKBM

Nkr

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

Aker BioMarine launched a new krill oil brand in Costco during Q4 2025, with the listing showing strong initial results and attracting new customers in a key U.S. retail channel.

For Q1 2026, the company forecasts krill oil revenues to grow between 15% and 30% year-over-year, signaling robust underlying demand and strong pricing within its main ingredients business.

Consumer Health Products revenue dropped 8% year-over-year to USD 26.9 million in Q4 2025, reflecting ongoing weakness in drugstore channels and soft demand in end markets.

The Emerging Business segment posted an adjusted EBITDA loss of USD 0.5 million in Q4 2025, highlighting continued cash outflows and uncertainty regarding future profitability.

Data summarised monthly by Lightyear AI. Last updated on 16 May 2026.

About Aker BioMarine AS

Ticker

Primary listing

Employees

Headquarters

AKBM Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Buy Nkr AKBM

Upcoming events

No upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

Aker BioMarine AS/Nkr AKBM

About Aker BioMarine AS

Ticker

Primary listing

Employees

Headquarters

AKBM Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Buy Nkr AKBM

Upcoming events

No upcoming events

What’s the current market cap for Aker BioMarine AS stock?

What is the P/E ratio for Aker BioMarine AS stock?

Does Aker BioMarine AS stock pay dividends?

When is the next Aker BioMarine AS dividend payment date?

What is the beta indicator for Aker BioMarine AS?

Bulls say / Bears say